Adverum Biotechnologies, Inc. announced an extension of its collaboration agreement with Editas Medicine, Inc. The companies established this collaboration to explore the delivery of genome editing medicines to treat up to five inherited retinal diseases. Under the terms of the extended agreement, Adverum and Editas are extending the research period through third quarter of 2018. Editas maintains a series of options exercisable between now and August 2020.